• Toremifene vs Tamoxifen in Advanced Breast Cancer: Systemati

  2026-06-10

  This Cochrane systematic review rigorously compared Toremifene, an oral selective estrogen receptor modulator, with tamoxifen in the management of advanced breast cancer. The findings highlight comparable efficacy and safety profiles, providing a robust evidence base for researchers studying hormone receptor modulation and estrogen receptor signaling pathway interventions.

• Guideline-Based Advances in Cutaneous Candidiasis Therapy

  2026-06-09

  This article examines the 2009 Japanese guideline on mucocutaneous candidiasis, highlighting evidence-based diagnostic strategies and the central role of imidazole antifungals—specifically Neticonazole Hydrochloride—in topical treatment. The guideline's findings shape current standards for clinical management and inform translational research protocols.

• Resveratrol as a SIRT1 Activator: Precision in Neurodegenera

  2026-06-09

  Explore how Resveratrol, a leading SIRT1 activator, provides mechanistic and workflow precision in neurodegeneration research. This cornerstone article uniquely dissects solubility, dosing, and mitochondrial biogenesis for reproducible, translatable results.

• Protease Inhibitor Cocktail EDTA-Free: Precision in Apoptosi

  2026-06-08

  Explore how the Protease Inhibitor Cocktail EDTA-Free empowers advanced apoptosis and phosphorylation assays by preserving protein integrity without EDTA interference. This article reveals new insights grounded in recent leukemia research and positions APExBIO's solution as uniquely enabling for mechanistic cell signaling studies.

• Cy3 Goat Anti-Mouse IgG (H+L) Antibody: Protocol Guide

  2026-06-08

  The Cy3 Goat Anti-Mouse IgG (H+L) Antibody enables sensitive and specific detection of mouse IgG in fluorescence-based assays including immunofluorescence, flow cytometry, and western blotting. This reagent addresses challenges in signal amplification and workflow reproducibility, but is not validated for diagnostic or clinical applications.

• PD0325901 in Precision Oncology: Mechanistic Depth and Assay

  2026-06-07

  Explore how PD0325901, a selective MEK inhibitor, enables advanced mechanistic studies of RAS/RAF/MEK/ERK signaling in cancer. This article provides unique insights into assay optimization and stem cell fate analysis beyond conventional workflows.

• Phosphatase Inhibitor Cocktail 1 (100X in DMSO): Application

  2026-06-06

  Phosphatase Inhibitor Cocktail 1 (100X in DMSO) prevents dephosphorylation of proteins during sample preparation, ensuring the accuracy of phosphorylation-dependent studies. It is suitable for workflows such as Western blotting, phosphoproteomic analysis, and kinase assays, but should not be used for diagnostic or medical applications.

• EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1

  2026-06-05

  EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1-amine hydrochloride) is a water-soluble carbodiimide reagent designed for efficient amide bond formation in in vitro peptide synthesis and bioconjugation workflows. It is not validated for in vivo or clinical use. Researchers should follow best practices for handling and protocol setup to maximize coupling efficiency and minimize failure modes.

• Phytol in Translational Research: Mechanisms, Models, and Vi

  2026-06-05

  This thought-leadership article explores Phytol’s dual roles in RXR signaling and GABAergic modulation, providing mechanistic context, protocol guidance, and strategic insights for translational researchers. Drawing from the latest lyotropic assembly research and real-world assay workflows, it positions Phytol as a linchpin for next-generation nuclear receptor and neuropharmacology studies, while mapping its unique translational potential and limitations.

• Topotecan’s Mechanism and Clinical Role: Lessons for DNA Dam

  2026-06-04

  This review details the development and clinical pharmacology of topotecan, a topoisomerase I inhibitor, highlighting its unique mechanism, pharmacokinetics, and efficacy in solid tumor treatment. The findings inform the broader context of DNA damage pathway research and support optimized experimental design when studying DNA repair and apoptosis in cancer models.

• Hexa-acylated LPS from Gut Microbiota Enhances Cancer Immuno

  2026-06-04

  This study identifies hexa-acylated lipopolysaccharides (LPS) from gut bacteria as key enhancers of anti-PD-1 immunotherapy efficacy. Functional metagenomics and mouse models reveal that the structural diversity of LPS, rather than bacterial taxonomy alone, predicts and modulates immune checkpoint response.

• Cy5 Maleimide: Protein Labeling Power for Phase Separation A

  2026-06-03

  Unlock precise, site-specific fluorescent labeling with Cy5 maleimide (non-sulfonated) for advanced protein tracking and phase separation studies. This guide demystifies workflow optimization, troubleshooting, and the latest research-driven advantages for fluorescence imaging of proteins.

• Dual-Action Kinase Inhibitors Accelerate p38α Dephosphorylat

  2026-06-03

  This study reveals that certain kinase inhibitors not only block p38α MAP kinase activity but also promote its dephosphorylation by stabilizing unique activation loop conformations. These findings uncover a dual mechanism that may inform the design of more targeted inflammation and hypertension therapies.

• Optimizing cDNA Synthesis with HyperScript™ Reverse Transcri

  2026-06-02

  HyperScript™ Reverse Transcriptase from APExBIO transforms RNA-to-cDNA workflows, excelling with low-abundance and structurally complex templates. Discover how enhanced thermal stability, reduced RNase H activity, and practical troubleshooting empower robust gene expression studies, as shown in advanced transcriptomic research.

• Ziprasidone Hydrochloride: Mechanistic Insights & Advanced F

  2026-06-02

  Explore Ziprasidone Hydrochloride’s dual role as a serotonin and dopamine receptor antagonist and GOT1 inhibitor, with a focus on advanced formulation strategies and mechanistic detail. This article provides in-depth, evidence-backed perspectives for researchers using Ziprasidone HCl in neuroscience and oncology contexts.

449 records 15/30 page Previous Next First page 上5页 1112131415 下5页 Last page